קומפיוגן בע"מ

Compugen discovers novel drug targets through a unique, predictive, computational process that combines human biology predictions derived from genome analysis combined with experimental and disease information derived from analysis of vast amounts of publicly available, as well as proprietary data. The comprehensive data analysis is designed to identify first-in-class drug target candidates, primarily in the field of immuno-oncology, which are difficult to identify using traditional computational or experimental approaches. An important aspect of Compugen’s predictive development efforts also includes the creation of three main technology platforms, LEADS, MED and LINKS, which integrate the Company’s scientific understandings and predictive models.

Pharmaceutical, Biotechnology and other Life Science Organizations

Anat Cohen-Dayag - President & CEO

Zurit Levine - SVP, Technology Innovation

David Silberman - CFO